pulsed field ablation to irreversibly electroporate tissue and treat af

Conditions: Atrial Fibrillation

Summary: the study is a prospective, multi-center, non-randomized, unblinded worldwide pre-market clinical study. the purpose of the study is to provide data demonstrating the safety and effectiveness of the pulseselect™ pfa system for the treatment of atrial fibrillation (af). the study will also provide first in human insights into clinical safety and device function of the pulseselect pfa system for pulmonary vein isolation (pvi) as a treatment for af. to this end, the clinical study has been designed into phases (pilot and pivotal), with each phase comprising a separate data set that will be analyzed and reported on per the below objectives.


Eligibility criteria:
inclusion criteria: 1. failure of at least one aad (class i or iii) for af as evidenced by recurrent symptomatic af, or intolerable side effects due to aad. 2. a diagnosis of recurrent symptomatic paroxysmal or persistent af: 1. symptomatic paroxysmal af, which is defined as af that terminates spontaneously or with intervention within 7 days of onset, documented by the following: 1. physician's note indicating at least 2 symptomatic paroxysmal af episodes occurring within 6 months prior to enrollment; and 2. at least 1 ecg documented af episode from any form of rhythm monitoring within 12 months prior to enrollment or 2. symptomatic persistent af, which is defined as continuous af sustained beyond 7 days and less than 1 year, documented by the following: 1. physician's note indicating at least 1 symptomatic persistent af episode occurring within 6 months prior to enrollment; and 2. any 24-hour continuous ecg recording documenting continuous af within 6 months prior to enrollment; or 2 ecgs from any form of rhythm monitoring taken at least 7 days apart, both showing continuous af within 6 months prior to enrollment 3. age 18 through 80 years old (or older than 18 if required by local law) exclusion criteria: 1. long-standing persistent af (continuous af that is sustained \>12 months) 2. left atrial diameter \> 5.0 cm (anteroposterior) 3. prior left atrial ablation or surgical procedure (including left atrial appendage closures) 4. planned laa closure procedure or implant of a permanent pacemaker, biventricular pacemaker, loop recorder/insertable cardiac monitor (icm), or any type of implantable cardiac defibrillator (with or without biventricular pacing function) for any time during the follow-up period 5. patient who is not on oral anticoagulation therapy for at least 3 weeks prior to the ablation procedure 6. presence of a permanent pacemaker, biventricular pacemaker, loop recorder/insertable cardiac monitor (icm), or any type of implantable cardiac defibrillator (with or without biventricular pacing function) 7. presence of any pulmonary vein stents 8. presence of any pre-existing pulmonary vein stenosis 9. pre-existing hemidiaphragmatic paralysis 10. presence of any cardiac valve prosthesis 11. moderate to severe mitral valve stenosis 12. more than moderate mitral regurgitation (i.e., 3+ or 4+ mr) 13. any cardiac surgery, myocardial infarction, pci / ptca or coronary artery stenting which occurred during the 3-month interval preceding the consent date 14. unstable angina 15. nyha class iii or iv congestive heart failure or documented left ventricular ejection fraction (lvef) less than or equal to 35% measure by acceptable cardiac testing (e.g. tte) 16. primary pulmonary hypertension 17. rheumatic heart disease 18. thrombocytosis, thrombocytopenia 19. any condition contraindicating chronic anticoagulation 20. active systemic infection 21. hypertrophic cardiomyopathy 22. known reversible causes of af, including but not limited to uncontrolled hyperthyroidism, severe untreated obstructive sleep apnea, and acute alcohol toxicity 23. any cerebral ischemic event (strokes or tias) which occurred during the 6-month interval preceding the consent date 24. history of thromboembolic event within the past 6 months or evidence of intracardiac thrombus at the time of the procedure 25. any woman known to be pregnant or breastfeeding, or any woman of childbearing potential who is not on a reliable form of birth regulation method or abstinence 26. patient with life expectancy that makes it unlikely 12 months of follow-up will be completed 27. current or anticipated participation in any other clinical trial of a drug, device or biologic during the duration of the study not pre-approved by medtronic 28. known allergies or hypersensitivities to adhesives 29. unwilling or unable to comply fully with study procedures and follow-up 30. unable to provide own informed consent